摘要：[目的] 研究化合物（vatalbinoside A）在治疗痛风中应用。[方法] 实验分6组，分别为对照组，正常给药组, 别嘌呤醇组，模型组，模型给药组和模型加别嘌呤醇组。 用剂量为250mg/kg的氧嗪酸钾盐给小鼠灌胃，建立高尿酸血症模型, 每天一次，灌胃体积为10ml/kg，连续7天。第4天给药后上代谢笼，收集48小时尿液， 分别测定尿液尿酸、尿肌酐和尿液尿素氮含量。最后一次给药后1小时摘眼球取血, 测量血清尿酸、血清肌酐和血清尿素氮含量. [结果] 250mg/kg氧嗪酸钾盐能显著提高小鼠血清中尿酸、肌酐和尿素氮含量，而尿液中尿酸、肌酐和尿素氮含量则显著减少； 模型给药组能显著逆转这种现象，逆转效果与别嘌呤醇作用效果相当。 [结论]化合物vatalbinoside A具有显著的降尿酸作用,可用于痛风的临床治疗。
关键词 : 痛风 ; 高尿酸血症 ; 别嘌呤醇；尿酸；肌酐；尿素氮
Abstract: [Purpose] To study the effects of the compound (vatalbinoside A) on treating gout. [Method] Mice were divided into six groups, respectively, for the normal groups (control, Vatalbinoside A, allopurinol), and model groups(control, Vatalbinoside A, allopurinol). Hyperuricemic mice were orally administered in a volume of 10 ml/kg by gavage 250 mg/kg oxonate once daily for seven consecutive days. Mice were transferred into metabolic cages after 4-day treatment. Urine in 48 hours were collected to drtermine the content of urine uric acid, urine creatinine and urine urea nitrogen. Eyeballs were picked out and the blood was collected to determine the content of serum uric acid, serum creatinine and blood urea nitrogen . [Results] 250mg/kg oxonate significantly improve the content of serum uric acid, serum creatinine and blood urea nitrogen ,while the content of urine uric acid, urine creatinine and urine urea nitrogen in the urine were notably decreased in mice. The results of Vatalbinoside A model group wer
obviously reversed as the results of allopurinol model group.[Conclusion] Vatalbinoside A has the distinct hypouricemic effect and could be used to treat gout disease clinically.
Keywords: Gout; Hyperuricemia; Allopurinol; Uric Acid; Creatinine; Urea Nitrogen
